ATE527345T1 - Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten - Google Patents

Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten

Info

Publication number
ATE527345T1
ATE527345T1 AT06829900T AT06829900T ATE527345T1 AT E527345 T1 ATE527345 T1 AT E527345T1 AT 06829900 T AT06829900 T AT 06829900T AT 06829900 T AT06829900 T AT 06829900T AT E527345 T1 ATE527345 T1 AT E527345T1
Authority
AT
Austria
Prior art keywords
chimeric fusion
fusion protein
nucleotide sequences
protein
sequences coding
Prior art date
Application number
AT06829900T
Other languages
English (en)
Inventor
Christian Scholz
Peter Schaarschmidt
Urban Schmitt
Elke Faatz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE527345T1 publication Critical patent/ATE527345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06829900T 2006-01-03 2006-12-29 Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten ATE527345T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06000056 2006-01-03
EP06009106 2006-05-03
PCT/EP2006/012599 WO2007077008A1 (en) 2006-01-03 2006-12-29 Chimaeric fusion protein with superior chaperone and folding activities

Publications (1)

Publication Number Publication Date
ATE527345T1 true ATE527345T1 (de) 2011-10-15

Family

ID=37908055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06829900T ATE527345T1 (de) 2006-01-03 2006-12-29 Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten

Country Status (8)

Country Link
US (2) US7947494B2 (de)
EP (1) EP1971684B1 (de)
JP (1) JP4871960B2 (de)
CN (1) CN101351550B (de)
AT (1) ATE527345T1 (de)
CA (1) CA2636075C (de)
ES (1) ES2375863T3 (de)
WO (1) WO2007077008A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2127678A1 (de) 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA als Werkzeug für recombinante Protein-und Enzym-technologie
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
EP2706115A1 (de) * 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperon-Chaperon-Fusionspolypeptide zur Reduzierung der Störungen und Stabilisierung von Immunoassays
AR093778A1 (es) * 2012-11-08 2015-06-24 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
MA38165A1 (fr) * 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
WO2015044083A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
US10316322B2 (en) 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
EP3247378B8 (de) 2015-01-09 2023-08-23 Revolution Medicines, Inc. Makrozyklische verbindungen mit beteiligung an einer kooperativen bindung und medizinische verwendungen davon
CA2974343A1 (en) * 2015-02-13 2016-08-18 Sekisui Chemical Co., Ltd. Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method
JP6967002B2 (ja) * 2015-12-15 2021-11-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017215619A1 (zh) * 2016-06-15 2017-12-21 中国科学院上海生命科学研究院 在细胞内产生点突变的融合蛋白、其制备及用途
WO2018161038A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
IL269779B2 (en) * 2017-04-05 2026-04-01 Revolution Medicines Inc Methods and reagents for the analysis of protein-protein interfaces
JP7438545B2 (ja) * 2018-05-31 2024-02-27 トラスティーズ・オヴ・ダートマス・カレッジ ３次又は４次構造モチーフを用いた計算タンパク質設計
EP3956344A1 (de) * 2019-04-16 2022-02-23 University of Washington Amantadin-bindendes protein
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20250298022A1 (en) * 2022-05-03 2025-09-25 Roche Diagnostics Operations, Inc. Hiv gp41 variants for immunodiagnostic assays
WO2025098623A1 (en) 2023-11-09 2025-05-15 Roche Diagnostics Gmbh Transglutaminase substrates for labeling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010253A1 (en) 1995-09-15 1997-03-20 Merck & Co., Inc. A high throughput assay using fusion proteins
US5989868A (en) * 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
US7094884B2 (en) * 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US6962982B2 (en) * 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
MXPA03011455A (es) * 2001-06-22 2004-04-05 Hoffmann La Roche Complejo soluble que comprende glucoproteina de superficie retroviral.
US7094757B2 (en) * 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
EP1516928B1 (de) 2002-06-25 2010-02-17 Sekisui Chemical Co., Ltd. Expressionsvektor, wirt, fusionsprotein, verfahren zur herstellung von fusionsprotein und verfahren zur herstellung von protein
AU2004230803A1 (en) * 2003-04-18 2004-10-28 Chiba, Joe Immunogen, composition for immunological use and process for producing antibody using the same
US7604935B2 (en) * 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants

Also Published As

Publication number Publication date
EP1971684A1 (de) 2008-09-24
US20090042251A1 (en) 2009-02-12
US8247206B2 (en) 2012-08-21
WO2007077008A1 (en) 2007-07-12
ES2375863T3 (es) 2012-03-07
JP2009521938A (ja) 2009-06-11
CN101351550B (zh) 2012-10-10
CA2636075C (en) 2011-11-08
HK1128727A1 (en) 2009-11-06
US20110189754A1 (en) 2011-08-04
JP4871960B2 (ja) 2012-02-08
CA2636075A1 (en) 2007-07-12
CN101351550A (zh) 2009-01-21
EP1971684B1 (de) 2011-10-05
US7947494B2 (en) 2011-05-24

Similar Documents

Publication Publication Date Title
ATE527345T1 (de) Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten
CY1121049T1 (el) Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων
WO2010082804A3 (en) Method for producing physiologically active protein or peptide using immunoglobulin fragment
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
ATE492633T1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
MX348071B (es) Variantes de fc.
IL220164B (en) A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
EP4345163A3 (de) Gentechnische herstellung von nichtmenschlichen tieren zur herstellung chimärer antikörper
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
WO2005087810A3 (en) Dimeric fusion proteins and materials and methods for producing them
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
HK1223303A1 (zh) 凝血酶可裂解连接子
HK1232139A1 (zh) 生物标志物指导的多靶向免疫治疗
WO2007115724A3 (de) Method of increasing the in vivo recovery of therapeutic polypeptides
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
WO2014144911A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
EP2533792A4 (de) Chemisches präparat aus polyubiquitinketten
ATE515568T1 (de) Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide
NZ760008A (en) Uti fusion proteins
UA101142C2 (ru) Способ разработки антитела

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1971684

Country of ref document: EP